ACG Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-13,498
Closed -$2.48M 336
2021
Q2
$2.48M Sell
13,498
-1,776
-12% -$305K 0.31% 69
2021
Q1
$2.34M Sell
15,274
-18,915
-55% -$2.93M 0.31% 74
2020
Q4
$5.34M Buy
34,189
+443
+1% +$56.9K 0.74% 38
2020
Q3
$3.86M Sell
33,746
-4,932
-13% -$532K 0.58% 56
2020
Q2
$4.34M Buy
38,678
+4,605
+14% +$489K 0.71% 46
2020
Q1
$3.06M Buy
+34,073
New +$3.34M 0.57% 52

Other funds holding ALXN

ACG Wealth's ALXN Position: Q3 2021 in Review

ACG Wealth sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 13,498 shares — an estimated $2.48M sold.

ACG Wealth first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $5.34M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • ACG Wealth reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ACG Wealth sold 13,498 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.48M.
  • ACG Wealth first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • ACG Wealth's Alexion Pharmaceuticals position peaked at $5.34M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on ACG Wealth's 13F filing for Q3 2021, filed 1 Nov 2021.